Is Semaglutide Legit? Evidence Grade and Plain-English Verdict

Why the Claim Is Strong or Weak

Semaglutide is an FDA-approved GLP-1 receptor agonist with injectable and oral products for type 2 diabetes and chronic weight management. The Wegovy label now also covers cardiovascular risk reduction, accelerated approval for noncirrhotic MASH with moderate-to-advanced fibrosis, a 25 mg oral tablet, and a 7.2 mg weekly injection for adults with obesity.

Reviewed August 27, 2026. The current Wegovy label covers weekly injection, a daily 25 mg oral formulation, cardiovascular risk reduction, and accelerated approval for noncirrhotic MASH with moderate-to-advanced fibrosis. FDA approved Wegovy HD 7.2 mg in March 2026 for adults with obesity; altered skin sensation was reported more often at the higher dose. In January 2026 FDA found no increased risk of suicidal behavior or ideation with GLP-1 receptor agonists and requested removal of that warning from affected weight-management labels.

Top Evidence Signals

• Weight Loss: Level A, includes human evidence - STEP trials demonstrated ~15-17% body weight reduction with 2.4mg weekly dose. Consistent and significant weight loss across multiple large RCTs with thousands of participants.
• Blood Sugar Control: Level A, includes human evidence - Robust evidence for HbA1c reduction of 1.5-1.8% in type 2 diabetes. Superior to many existing diabetes medications in head-to-head trials.
• Cardiovascular Protection: Level A, includes human evidence - SELECT trial showed 20% reduction in major adverse cardiovascular events. Significant reduction in cardiovascular death, heart attack, and stroke risk.
• Kidney Protection: Level B, includes human evidence - FLOW trial demonstrated significant reduction in kidney disease progression in patients with type 2 diabetes and chronic kidney disease.
• MASH: Level A, includes human evidence - FDA granted accelerated approval in August 2025 for adults with noncirrhotic MASH and moderate-to-advanced fibrosis. Approval was based on histologic improvement; continued approval may depend on confirmation of clinical benefit.
• GI Side Effects: Level A, includes human evidence - Nausea, vomiting, and diarrhea are common side effects, especially during dose escalation. Usually transient but can lead to discontinuation in some patients.

Where Claims Usually Overreach

• Boxed warning: thyroid C-cell tumors in rodents
• Contraindicated with personal/family history of medullary thyroid carcinoma
• Risk of pancreatitis
• May worsen diabetic retinopathy
• Not for use with insulin or other GLP-1 agonists
• Gallbladder events reported

Primary Sources

1. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med, 2021.
2. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med, 2016.
3. Semaglutide and Cardiovascular Outcomes in Obesity (SELECT). N Engl J Med, 2023.
4. Two-Year Effects of Semaglutide on Weight (STEP 5). Nat Med, 2022.
5. Wegovy prescribing information. FDA Prescribing Information, 2026.
6. FDA approves treatment for MASH with moderate to advanced liver fibrosis. FDA Drug Approval, 2025.

Evidence Snapshot

Quick Answers

Related Guides

• tirzepatide
• liraglutide